SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma reports 27% rise in Q3 consolidated net profit

16 Feb 2022 Evaluate

Natco Pharma has reported results for third quarter ended December 31, 2021.

The company has reported rise of 30.90% in its net profit at Rs 71.60 crore for the quarter under review as compared to Rs 54.70 crore for the same quarter in the previous year. Total income of the company increased by 57.70% at Rs 561.10 crore for Q3FY22 as compared Rs 355.80 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 26.81% in its net profit at Rs 80.40 crore for the quarter under review as compared to Rs 63.40 crore for the same quarter in the previous year. Total income of the company increased by 53.03% at Rs 590.70 crore for Q3FY22 as compared Rs 386.00 crore for the corresponding quarter previous year.

Natco Pharma Share Price

1093.90 22.90 (2.14%)
24-Apr-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1618.50
Dr. Reddys Lab 1312.40
Cipla 1295.00
Zydus Lifesciences 930.00
Lupin 2285.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×